(Immunic) Shares of Immunic, Inc. fell 57% on Thursday after top-line data for its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium, failed to achieve primary endpoint.
The company said that the trial data of the selective DHODH inhibitor in patients with moderate to severe ulcerative colitis missed the endpoint of clinical remission in the dosed groups versus the placebo.
The company further stated that there were no substantial variations between the three active dose groups for the target patient population or for the trial’s other secondary endpoints.
Immunic still found that the administration of vidofludimus calcium in the trial was safe and well-tolerated, with no safety signals generated.
Immunc Chief Medical Officer Andreas Muehler expressed disappointment with the trial results, saying the company will explore further the mechanism behind the unexpected observation.
IMUX: NASDAQ is down -57.12%.
